nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—CYP3A4—Thiotepa—urinary bladder cancer	0.0722	0.386	CbGbCtD
Imiquimod—CYP1A2—Fluorouracil—urinary bladder cancer	0.0447	0.239	CbGbCtD
Imiquimod—CYP1A2—Etoposide—urinary bladder cancer	0.0373	0.2	CbGbCtD
Imiquimod—TLR7—prostate gland—urinary bladder cancer	0.0255	0.205	CbGeAlD
Imiquimod—TLR8—female reproductive system—urinary bladder cancer	0.0221	0.177	CbGeAlD
Imiquimod—CYP3A4—Etoposide—urinary bladder cancer	0.0196	0.105	CbGbCtD
Imiquimod—TLR7—female reproductive system—urinary bladder cancer	0.0139	0.112	CbGeAlD
Imiquimod—CYP3A4—Doxorubicin—urinary bladder cancer	0.0133	0.0713	CbGbCtD
Imiquimod—TLR8—lymph node—urinary bladder cancer	0.0129	0.104	CbGeAlD
Imiquimod—CYP1A2—urine—urinary bladder cancer	0.0128	0.103	CbGeAlD
Imiquimod—TLR7—vagina—urinary bladder cancer	0.0126	0.101	CbGeAlD
Imiquimod—CYP3A4—urine—urinary bladder cancer	0.00925	0.0745	CbGeAlD
Imiquimod—TLR7—lymph node—urinary bladder cancer	0.00814	0.0655	CbGeAlD
Imiquimod—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.0047	0.0303	CbGpPWpGaD
Imiquimod—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00459	0.0296	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—BIRC3—urinary bladder cancer	0.00444	0.0286	CbGpPWpGaD
Imiquimod—TLR8—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—S100B—urinary bladder cancer	0.00393	0.0253	CbGpPWpGaD
Imiquimod—TLR8—MyD88 dependent cascade initiated on endosome—S100B—urinary bladder cancer	0.00386	0.0248	CbGpPWpGaD
Imiquimod—TLR8—Toll Like Receptor 9 (TLR9) Cascade—S100B—urinary bladder cancer	0.00372	0.024	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—IFNA2—urinary bladder cancer	0.00362	0.0233	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—BIRC3—urinary bladder cancer	0.00337	0.0217	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00318	0.0205	CbGpPWpGaD
Imiquimod—CYP1A2—renal system—urinary bladder cancer	0.00313	0.0252	CbGeAlD
Imiquimod—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—S100B—urinary bladder cancer	0.00298	0.0192	CbGpPWpGaD
Imiquimod—TLR7—MyD88 dependent cascade initiated on endosome—S100B—urinary bladder cancer	0.00292	0.0188	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—IFNA2—urinary bladder cancer	0.00283	0.0182	CbGpPWpGaD
Imiquimod—TLR7—Toll Like Receptor 9 (TLR9) Cascade—S100B—urinary bladder cancer	0.00282	0.0182	CbGpPWpGaD
Imiquimod—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00281	0.0181	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—IFNA2—urinary bladder cancer	0.00275	0.0177	CbGpPWpGaD
Imiquimod—TLR8—Toll-Like Receptors Cascades—S100B—urinary bladder cancer	0.00264	0.017	CbGpPWpGaD
Imiquimod—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00246	0.0158	CbGpPWpGaD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00228	0.0147	CbGpPWpGaD
Imiquimod—CYP3A4—renal system—urinary bladder cancer	0.00226	0.0182	CbGeAlD
Imiquimod—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00217	0.014	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PRSS3—urinary bladder cancer	0.00216	0.0139	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—IFNA2—urinary bladder cancer	0.00214	0.0138	CbGpPWpGaD
Imiquimod—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00201	0.0129	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—S100B—urinary bladder cancer	0.002	0.0129	CbGpPWpGaD
Imiquimod—CYP3A4—female reproductive system—urinary bladder cancer	0.00181	0.0146	CbGeAlD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00176	0.0113	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00172	0.0111	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—CXCL8—urinary bladder cancer	0.00168	0.0108	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PRSS3—urinary bladder cancer	0.00163	0.0105	CbGpPWpGaD
Imiquimod—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00155	0.00997	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—BIRC3—urinary bladder cancer	0.00144	0.00927	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00133	0.00856	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—CXCL8—urinary bladder cancer	0.00131	0.00847	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—CXCL8—urinary bladder cancer	0.00128	0.00822	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00127	0.00815	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PRSS3—urinary bladder cancer	0.00126	0.00809	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.00123	0.00791	CbGpPWpGaD
Imiquimod—TLR8—Immune System—VHL—urinary bladder cancer	0.0012	0.00772	CbGpPWpGaD
Imiquimod—TLR8—Toll-like Receptor Signaling Pathway—TNF—urinary bladder cancer	0.00117	0.00755	CbGpPWpGaD
Imiquimod—TLR8—Immune System—MT2A—urinary bladder cancer	0.00113	0.00725	CbGpPWpGaD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00109	0.00704	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—BIRC3—urinary bladder cancer	0.00109	0.00702	CbGpPWpGaD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00108	0.00695	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00103	0.00664	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—CXCL8—urinary bladder cancer	0.000996	0.00642	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000978	0.0063	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000978	0.0063	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.00096	0.00618	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PRSS3—urinary bladder cancer	0.000952	0.00613	CbGpPWpGaD
Imiquimod—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000948	0.00611	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000942	0.00607	CbGpPWpGaD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—TNF—urinary bladder cancer	0.000915	0.00589	CbGpPWpGaD
Imiquimod—TLR7—Immune System—VHL—urinary bladder cancer	0.000908	0.00585	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—IFNA2—urinary bladder cancer	0.000906	0.00583	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000894	0.00576	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—TNF—urinary bladder cancer	0.000888	0.00572	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000887	0.00571	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—S100B—urinary bladder cancer	0.000856	0.00551	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MT2A—urinary bladder cancer	0.000854	0.0055	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000844	0.00544	CbGpPWpGaD
Imiquimod—TLR8—Immune System—BIRC3—urinary bladder cancer	0.000838	0.0054	CbGpPWpGaD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000833	0.00537	CbGpPWpGaD
Imiquimod—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000727	0.00468	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.00072	0.00463	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—TNF—urinary bladder cancer	0.000694	0.00447	CbGpPWpGaD
Imiquimod—TLR8—Immune System—RBX1—urinary bladder cancer	0.000688	0.00443	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IFNA2—urinary bladder cancer	0.000686	0.00442	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000684	0.00441	CbGpPWpGaD
Imiquimod—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000682	0.00439	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000673	0.00434	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—S100B—urinary bladder cancer	0.000649	0.00418	CbGpPWpGaD
Imiquimod—TLR7—Immune System—BIRC3—urinary bladder cancer	0.000635	0.00409	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—FGFR3—urinary bladder cancer	0.000623	0.00401	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000603	0.00389	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000595	0.00383	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00058	0.00374	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00058	0.00374	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000572	0.00368	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000572	0.00368	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000564	0.00363	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000536	0.00345	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CREBBP—urinary bladder cancer	0.00053	0.00341	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IFNA2—urinary bladder cancer	0.000527	0.0034	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000523	0.00337	CbGpPWpGaD
Imiquimod—TLR7—Immune System—RBX1—urinary bladder cancer	0.000522	0.00336	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000516	0.00332	CbGpPWpGaD
Imiquimod—TLR8—Immune System—S100B—urinary bladder cancer	0.000499	0.00321	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—FGFR3—urinary bladder cancer	0.000472	0.00304	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000471	0.00303	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000466	0.003	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000465	0.00299	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000459	0.00296	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—ERBB2—urinary bladder cancer	0.000444	0.00286	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000442	0.00284	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000442	0.00284	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000435	0.0028	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000428	0.00276	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000415	0.00268	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000406	0.00261	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000404	0.0026	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CREBBP—urinary bladder cancer	0.000402	0.00259	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IFNA2—urinary bladder cancer	0.0004	0.00257	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000398	0.00257	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000398	0.00256	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CDKN1A—urinary bladder cancer	0.000379	0.00244	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PTEN—urinary bladder cancer	0.000379	0.00244	CbGpPWpGaD
Imiquimod—TLR7—Immune System—S100B—urinary bladder cancer	0.000378	0.00243	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000364	0.00234	CbGpPWpGaD
Imiquimod—TLR8—Immune System—FGFR3—urinary bladder cancer	0.000363	0.00234	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—EP300—urinary bladder cancer	0.000361	0.00233	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000359	0.00231	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—SRC—urinary bladder cancer	0.000351	0.00226	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000349	0.00225	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—ERBB2—urinary bladder cancer	0.000336	0.00217	CbGpPWpGaD
Imiquimod—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000324	0.000607	CcSEcCtD
Imiquimod—Haemoglobin—Methotrexate—urinary bladder cancer	0.000324	0.000607	CcSEcCtD
Imiquimod—Haemorrhage—Methotrexate—urinary bladder cancer	0.000322	0.000604	CcSEcCtD
Imiquimod—Asthenia—Gemcitabine—urinary bladder cancer	0.000321	0.000602	CcSEcCtD
Imiquimod—Pharyngitis—Methotrexate—urinary bladder cancer	0.00032	0.000599	CcSEcCtD
Imiquimod—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000318	0.000596	CcSEcCtD
Imiquimod—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000318	0.000596	CcSEcCtD
Imiquimod—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000317	0.000595	CcSEcCtD
Imiquimod—Pruritus—Gemcitabine—urinary bladder cancer	0.000316	0.000593	CcSEcCtD
Imiquimod—Nausea—Thiotepa—urinary bladder cancer	0.000316	0.000592	CcSEcCtD
Imiquimod—Urethral disorder—Methotrexate—urinary bladder cancer	0.000316	0.000592	CcSEcCtD
Imiquimod—Sinusitis—Epirubicin—urinary bladder cancer	0.000315	0.000591	CcSEcCtD
Imiquimod—Feeling abnormal—Etoposide—urinary bladder cancer	0.000315	0.00059	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000313	0.00202	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000313	0.00202	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000312	0.000586	CcSEcCtD
Imiquimod—Pruritus—Fluorouracil—urinary bladder cancer	0.000311	0.000583	CcSEcCtD
Imiquimod—Infestation—Doxorubicin—urinary bladder cancer	0.000311	0.000582	CcSEcCtD
Imiquimod—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000311	0.000582	CcSEcCtD
Imiquimod—Visual impairment—Methotrexate—urinary bladder cancer	0.00031	0.000582	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000309	0.00199	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CREBBP—urinary bladder cancer	0.000309	0.00199	CbGpPWpGaD
Imiquimod—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000308	0.000577	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—EGFR—urinary bladder cancer	0.000308	0.00198	CbGpPWpGaD
Imiquimod—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000307	0.000576	CcSEcCtD
Imiquimod—TLR8—Immune System—CDH1—urinary bladder cancer	0.000307	0.00197	CbGpPWpGaD
Imiquimod—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000306	0.000574	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000305	0.00196	CbGpPWpGaD
Imiquimod—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000304	0.000571	CcSEcCtD
Imiquimod—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000304	0.000571	CcSEcCtD
Imiquimod—Urticaria—Etoposide—urinary bladder cancer	0.000303	0.000569	CcSEcCtD
Imiquimod—Haemoglobin—Epirubicin—urinary bladder cancer	0.000303	0.000568	CcSEcCtD
Imiquimod—Rhinitis—Epirubicin—urinary bladder cancer	0.000302	0.000566	CcSEcCtD
Imiquimod—Abdominal pain—Etoposide—urinary bladder cancer	0.000302	0.000566	CcSEcCtD
Imiquimod—Body temperature increased—Etoposide—urinary bladder cancer	0.000302	0.000566	CcSEcCtD
Imiquimod—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000302	0.000566	CcSEcCtD
Imiquimod—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000302	0.000566	CcSEcCtD
Imiquimod—Haemorrhage—Epirubicin—urinary bladder cancer	0.000301	0.000565	CcSEcCtD
Imiquimod—Eye disorder—Methotrexate—urinary bladder cancer	0.000301	0.000564	CcSEcCtD
Imiquimod—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000301	0.000564	CcSEcCtD
Imiquimod—Tinnitus—Methotrexate—urinary bladder cancer	0.0003	0.000563	CcSEcCtD
Imiquimod—Asthenia—Cisplatin—urinary bladder cancer	0.000299	0.000561	CcSEcCtD
Imiquimod—Pharyngitis—Epirubicin—urinary bladder cancer	0.000299	0.000561	CcSEcCtD
Imiquimod—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000298	0.000558	CcSEcCtD
Imiquimod—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000296	0.000555	CcSEcCtD
Imiquimod—Urethral disorder—Epirubicin—urinary bladder cancer	0.000295	0.000554	CcSEcCtD
Imiquimod—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000294	0.000551	CcSEcCtD
Imiquimod—Angiopathy—Methotrexate—urinary bladder cancer	0.000292	0.000548	CcSEcCtD
Imiquimod—Sinusitis—Doxorubicin—urinary bladder cancer	0.000291	0.000546	CcSEcCtD
Imiquimod—Immune system disorder—Methotrexate—urinary bladder cancer	0.000291	0.000545	CcSEcCtD
Imiquimod—Dizziness—Fluorouracil—urinary bladder cancer	0.000291	0.000545	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—KRAS—urinary bladder cancer	0.000291	0.00187	CbGpPWpGaD
Imiquimod—Visual impairment—Epirubicin—urinary bladder cancer	0.00029	0.000545	CcSEcCtD
Imiquimod—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00029	0.000544	CcSEcCtD
Imiquimod—Chills—Methotrexate—urinary bladder cancer	0.000289	0.000542	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000288	0.00185	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CDKN1A—urinary bladder cancer	0.000288	0.00185	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PTEN—urinary bladder cancer	0.000287	0.00185	CbGpPWpGaD
Imiquimod—Diarrhoea—Cisplatin—urinary bladder cancer	0.000285	0.000535	CcSEcCtD
Imiquimod—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000285	0.000534	CcSEcCtD
Imiquimod—Alopecia—Methotrexate—urinary bladder cancer	0.000285	0.000534	CcSEcCtD
Imiquimod—Vomiting—Gemcitabine—urinary bladder cancer	0.000284	0.000533	CcSEcCtD
Imiquimod—Mental disorder—Methotrexate—urinary bladder cancer	0.000282	0.000529	CcSEcCtD
Imiquimod—Rash—Gemcitabine—urinary bladder cancer	0.000282	0.000529	CcSEcCtD
Imiquimod—Dermatitis—Gemcitabine—urinary bladder cancer	0.000282	0.000528	CcSEcCtD
Imiquimod—Eye disorder—Epirubicin—urinary bladder cancer	0.000282	0.000528	CcSEcCtD
Imiquimod—Hypersensitivity—Etoposide—urinary bladder cancer	0.000281	0.000528	CcSEcCtD
Imiquimod—Tinnitus—Epirubicin—urinary bladder cancer	0.000281	0.000527	CcSEcCtD
Imiquimod—Erythema—Methotrexate—urinary bladder cancer	0.00028	0.000526	CcSEcCtD
Imiquimod—Malnutrition—Methotrexate—urinary bladder cancer	0.00028	0.000526	CcSEcCtD
Imiquimod—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00028	0.000525	CcSEcCtD
Imiquimod—Headache—Gemcitabine—urinary bladder cancer	0.00028	0.000525	CcSEcCtD
Imiquimod—Flushing—Epirubicin—urinary bladder cancer	0.00028	0.000524	CcSEcCtD
Imiquimod—Vomiting—Fluorouracil—urinary bladder cancer	0.00028	0.000524	CcSEcCtD
Imiquimod—Rhinitis—Doxorubicin—urinary bladder cancer	0.00028	0.000524	CcSEcCtD
Imiquimod—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000279	0.000523	CcSEcCtD
Imiquimod—Rash—Fluorouracil—urinary bladder cancer	0.000277	0.00052	CcSEcCtD
Imiquimod—Dermatitis—Fluorouracil—urinary bladder cancer	0.000277	0.000519	CcSEcCtD
Imiquimod—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000277	0.000519	CcSEcCtD
Imiquimod—Headache—Fluorouracil—urinary bladder cancer	0.000275	0.000517	CcSEcCtD
Imiquimod—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000275	0.000516	CcSEcCtD
Imiquimod—TLR7—Immune System—FGFR3—urinary bladder cancer	0.000275	0.00177	CbGpPWpGaD
Imiquimod—Asthenia—Etoposide—urinary bladder cancer	0.000274	0.000514	CcSEcCtD
Imiquimod—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000274	0.000514	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—EP300—urinary bladder cancer	0.000274	0.00176	CbGpPWpGaD
Imiquimod—Angiopathy—Epirubicin—urinary bladder cancer	0.000273	0.000513	CcSEcCtD
Imiquimod—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000273	0.000513	CcSEcCtD
Imiquimod—Immune system disorder—Epirubicin—urinary bladder cancer	0.000272	0.00051	CcSEcCtD
Imiquimod—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000272	0.000509	CcSEcCtD
Imiquimod—Back pain—Methotrexate—urinary bladder cancer	0.000271	0.000508	CcSEcCtD
Imiquimod—Chills—Epirubicin—urinary bladder cancer	0.00027	0.000507	CcSEcCtD
Imiquimod—Pruritus—Etoposide—urinary bladder cancer	0.00027	0.000507	CcSEcCtD
Imiquimod—Arrhythmia—Epirubicin—urinary bladder cancer	0.000269	0.000505	CcSEcCtD
Imiquimod—Visual impairment—Doxorubicin—urinary bladder cancer	0.000269	0.000504	CcSEcCtD
Imiquimod—Alopecia—Epirubicin—urinary bladder cancer	0.000266	0.000499	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—SRC—urinary bladder cancer	0.000266	0.00171	CbGpPWpGaD
Imiquimod—Nausea—Gemcitabine—urinary bladder cancer	0.000266	0.000498	CcSEcCtD
Imiquimod—Vomiting—Cisplatin—urinary bladder cancer	0.000265	0.000497	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000265	0.0017	CbGpPWpGaD
Imiquimod—Mental disorder—Epirubicin—urinary bladder cancer	0.000264	0.000495	CcSEcCtD
Imiquimod—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000264	0.000494	CcSEcCtD
Imiquimod—Rash—Cisplatin—urinary bladder cancer	0.000263	0.000493	CcSEcCtD
Imiquimod—Dermatitis—Cisplatin—urinary bladder cancer	0.000263	0.000492	CcSEcCtD
Imiquimod—Erythema—Epirubicin—urinary bladder cancer	0.000262	0.000492	CcSEcCtD
Imiquimod—Malnutrition—Epirubicin—urinary bladder cancer	0.000262	0.000492	CcSEcCtD
Imiquimod—Diarrhoea—Etoposide—urinary bladder cancer	0.000261	0.00049	CcSEcCtD
Imiquimod—Nausea—Fluorouracil—urinary bladder cancer	0.000261	0.00049	CcSEcCtD
Imiquimod—Eye disorder—Doxorubicin—urinary bladder cancer	0.000261	0.000489	CcSEcCtD
Imiquimod—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00026	0.000488	CcSEcCtD
Imiquimod—Tinnitus—Doxorubicin—urinary bladder cancer	0.00026	0.000487	CcSEcCtD
Imiquimod—Flushing—Doxorubicin—urinary bladder cancer	0.000259	0.000485	CcSEcCtD
Imiquimod—TLR8—Immune System—ERBB2—urinary bladder cancer	0.000259	0.00167	CbGpPWpGaD
Imiquimod—Back pain—Epirubicin—urinary bladder cancer	0.000254	0.000476	CcSEcCtD
Imiquimod—Angiopathy—Doxorubicin—urinary bladder cancer	0.000253	0.000474	CcSEcCtD
Imiquimod—Malaise—Methotrexate—urinary bladder cancer	0.000253	0.000474	CcSEcCtD
Imiquimod—Dizziness—Etoposide—urinary bladder cancer	0.000253	0.000474	CcSEcCtD
Imiquimod—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000252	0.000472	CcSEcCtD
Imiquimod—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000251	0.000471	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000251	0.00161	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000251	0.00161	CbGpPWpGaD
Imiquimod—Chills—Doxorubicin—urinary bladder cancer	0.00025	0.000469	CcSEcCtD
Imiquimod—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000249	0.000467	CcSEcCtD
Imiquimod—Nausea—Cisplatin—urinary bladder cancer	0.000248	0.000464	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—HRAS—urinary bladder cancer	0.000247	0.00159	CbGpPWpGaD
Imiquimod—Alopecia—Doxorubicin—urinary bladder cancer	0.000246	0.000462	CcSEcCtD
Imiquimod—Cough—Methotrexate—urinary bladder cancer	0.000245	0.000459	CcSEcCtD
Imiquimod—Mental disorder—Doxorubicin—urinary bladder cancer	0.000244	0.000458	CcSEcCtD
Imiquimod—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000243	0.000456	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000243	0.00157	CbGpPWpGaD
Imiquimod—Convulsion—Methotrexate—urinary bladder cancer	0.000243	0.000455	CcSEcCtD
Imiquimod—Vomiting—Etoposide—urinary bladder cancer	0.000243	0.000455	CcSEcCtD
Imiquimod—Malnutrition—Doxorubicin—urinary bladder cancer	0.000243	0.000455	CcSEcCtD
Imiquimod—Erythema—Doxorubicin—urinary bladder cancer	0.000243	0.000455	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000242	0.00156	CbGpPWpGaD
Imiquimod—Agitation—Epirubicin—urinary bladder cancer	0.000241	0.000452	CcSEcCtD
Imiquimod—Rash—Etoposide—urinary bladder cancer	0.000241	0.000452	CcSEcCtD
Imiquimod—Dermatitis—Etoposide—urinary bladder cancer	0.000241	0.000451	CcSEcCtD
Imiquimod—Headache—Etoposide—urinary bladder cancer	0.000239	0.000449	CcSEcCtD
Imiquimod—Arthralgia—Methotrexate—urinary bladder cancer	0.000239	0.000447	CcSEcCtD
Imiquimod—Chest pain—Methotrexate—urinary bladder cancer	0.000239	0.000447	CcSEcCtD
Imiquimod—Myalgia—Methotrexate—urinary bladder cancer	0.000239	0.000447	CcSEcCtD
Imiquimod—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000239	0.00154	CbGpPWpGaD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000237	0.000444	CcSEcCtD
Imiquimod—Malaise—Epirubicin—urinary bladder cancer	0.000237	0.000444	CcSEcCtD
Imiquimod—Discomfort—Methotrexate—urinary bladder cancer	0.000236	0.000442	CcSEcCtD
Imiquimod—Syncope—Epirubicin—urinary bladder cancer	0.000235	0.000441	CcSEcCtD
Imiquimod—Back pain—Doxorubicin—urinary bladder cancer	0.000235	0.00044	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000235	0.00151	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL2—urinary bladder cancer	0.000234	0.00151	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CREBBP—urinary bladder cancer	0.000234	0.00151	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—EGFR—urinary bladder cancer	0.000233	0.0015	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000232	0.0015	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDH1—urinary bladder cancer	0.000232	0.0015	CbGpPWpGaD
Imiquimod—Palpitations—Epirubicin—urinary bladder cancer	0.000232	0.000435	CcSEcCtD
Imiquimod—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000231	0.000432	CcSEcCtD
Imiquimod—Cough—Epirubicin—urinary bladder cancer	0.000229	0.000429	CcSEcCtD
Imiquimod—Convulsion—Epirubicin—urinary bladder cancer	0.000227	0.000426	CcSEcCtD
Imiquimod—Infection—Methotrexate—urinary bladder cancer	0.000227	0.000426	CcSEcCtD
Imiquimod—Nausea—Etoposide—urinary bladder cancer	0.000227	0.000425	CcSEcCtD
Imiquimod—Hypertension—Epirubicin—urinary bladder cancer	0.000226	0.000425	CcSEcCtD
Imiquimod—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000225	0.000422	CcSEcCtD
Imiquimod—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000224	0.000421	CcSEcCtD
Imiquimod—Arthralgia—Epirubicin—urinary bladder cancer	0.000223	0.000419	CcSEcCtD
Imiquimod—Myalgia—Epirubicin—urinary bladder cancer	0.000223	0.000419	CcSEcCtD
Imiquimod—Chest pain—Epirubicin—urinary bladder cancer	0.000223	0.000419	CcSEcCtD
Imiquimod—Agitation—Doxorubicin—urinary bladder cancer	0.000223	0.000418	CcSEcCtD
Imiquimod—Anxiety—Epirubicin—urinary bladder cancer	0.000223	0.000417	CcSEcCtD
Imiquimod—Skin disorder—Methotrexate—urinary bladder cancer	0.000222	0.000417	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000222	0.000416	CcSEcCtD
Imiquimod—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000221	0.000415	CcSEcCtD
Imiquimod—TLR8—Immune System—CDKN1A—urinary bladder cancer	0.000221	0.00142	CbGpPWpGaD
Imiquimod—Discomfort—Epirubicin—urinary bladder cancer	0.000221	0.000414	CcSEcCtD
Imiquimod—TLR8—Immune System—PTEN—urinary bladder cancer	0.000221	0.00142	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—KRAS—urinary bladder cancer	0.00022	0.00142	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000219	0.00141	CbGpPWpGaD
Imiquimod—Malaise—Doxorubicin—urinary bladder cancer	0.000219	0.00041	CcSEcCtD
Imiquimod—Dry mouth—Epirubicin—urinary bladder cancer	0.000218	0.00041	CcSEcCtD
Imiquimod—Anorexia—Methotrexate—urinary bladder cancer	0.000218	0.000409	CcSEcCtD
Imiquimod—Syncope—Doxorubicin—urinary bladder cancer	0.000218	0.000408	CcSEcCtD
Imiquimod—Palpitations—Doxorubicin—urinary bladder cancer	0.000214	0.000402	CcSEcCtD
Imiquimod—Oedema—Epirubicin—urinary bladder cancer	0.000214	0.000401	CcSEcCtD
Imiquimod—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000213	0.0004	CcSEcCtD
Imiquimod—Infection—Epirubicin—urinary bladder cancer	0.000213	0.000399	CcSEcCtD
Imiquimod—Cough—Doxorubicin—urinary bladder cancer	0.000212	0.000397	CcSEcCtD
Imiquimod—Shock—Epirubicin—urinary bladder cancer	0.000211	0.000395	CcSEcCtD
Imiquimod—TLR8—Immune System—EP300—urinary bladder cancer	0.00021	0.00135	CbGpPWpGaD
Imiquimod—Convulsion—Doxorubicin—urinary bladder cancer	0.00021	0.000394	CcSEcCtD
Imiquimod—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00021	0.000394	CcSEcCtD
Imiquimod—Hypertension—Doxorubicin—urinary bladder cancer	0.00021	0.000393	CcSEcCtD
Imiquimod—Tachycardia—Epirubicin—urinary bladder cancer	0.000209	0.000392	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000208	0.00134	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000208	0.00134	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000208	0.000391	CcSEcCtD
Imiquimod—Skin disorder—Epirubicin—urinary bladder cancer	0.000208	0.00039	CcSEcCtD
Imiquimod—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000207	0.000388	CcSEcCtD
Imiquimod—Insomnia—Methotrexate—urinary bladder cancer	0.000207	0.000388	CcSEcCtD
Imiquimod—Chest pain—Doxorubicin—urinary bladder cancer	0.000207	0.000387	CcSEcCtD
Imiquimod—Myalgia—Doxorubicin—urinary bladder cancer	0.000207	0.000387	CcSEcCtD
Imiquimod—Arthralgia—Doxorubicin—urinary bladder cancer	0.000207	0.000387	CcSEcCtD
Imiquimod—Anxiety—Doxorubicin—urinary bladder cancer	0.000206	0.000386	CcSEcCtD
Imiquimod—Paraesthesia—Methotrexate—urinary bladder cancer	0.000205	0.000385	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000205	0.000385	CcSEcCtD
Imiquimod—TLR8—Immune System—SRC—urinary bladder cancer	0.000205	0.00132	CbGpPWpGaD
Imiquimod—Discomfort—Doxorubicin—urinary bladder cancer	0.000204	0.000383	CcSEcCtD
Imiquimod—Anorexia—Epirubicin—urinary bladder cancer	0.000204	0.000383	CcSEcCtD
Imiquimod—Dyspnoea—Methotrexate—urinary bladder cancer	0.000204	0.000382	CcSEcCtD
Imiquimod—Somnolence—Methotrexate—urinary bladder cancer	0.000203	0.000381	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000203	0.00131	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000203	0.00131	CbGpPWpGaD
Imiquimod—Dry mouth—Doxorubicin—urinary bladder cancer	0.000202	0.000379	CcSEcCtD
Imiquimod—Dyspepsia—Methotrexate—urinary bladder cancer	0.000201	0.000378	CcSEcCtD
Imiquimod—Decreased appetite—Methotrexate—urinary bladder cancer	0.000199	0.000373	CcSEcCtD
Imiquimod—Oedema—Doxorubicin—urinary bladder cancer	0.000198	0.000371	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000198	0.00037	CcSEcCtD
Imiquimod—Fatigue—Methotrexate—urinary bladder cancer	0.000197	0.00037	CcSEcCtD
Imiquimod—Infection—Doxorubicin—urinary bladder cancer	0.000197	0.000369	CcSEcCtD
Imiquimod—TLR7—Immune System—ERBB2—urinary bladder cancer	0.000196	0.00126	CbGpPWpGaD
Imiquimod—Pain—Methotrexate—urinary bladder cancer	0.000196	0.000367	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000195	0.000366	CcSEcCtD
Imiquimod—Shock—Doxorubicin—urinary bladder cancer	0.000195	0.000365	CcSEcCtD
Imiquimod—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000194	0.000364	CcSEcCtD
Imiquimod—Insomnia—Epirubicin—urinary bladder cancer	0.000194	0.000363	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000193	0.00125	CbGpPWpGaD
Imiquimod—Tachycardia—Doxorubicin—urinary bladder cancer	0.000193	0.000363	CcSEcCtD
Imiquimod—Skin disorder—Doxorubicin—urinary bladder cancer	0.000192	0.000361	CcSEcCtD
Imiquimod—Paraesthesia—Epirubicin—urinary bladder cancer	0.000192	0.00036	CcSEcCtD
Imiquimod—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000192	0.000359	CcSEcCtD
Imiquimod—Dyspnoea—Epirubicin—urinary bladder cancer	0.000191	0.000358	CcSEcCtD
Imiquimod—Somnolence—Epirubicin—urinary bladder cancer	0.00019	0.000357	CcSEcCtD
Imiquimod—Anorexia—Doxorubicin—urinary bladder cancer	0.000189	0.000354	CcSEcCtD
Imiquimod—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000189	0.000353	CcSEcCtD
Imiquimod—Dyspepsia—Epirubicin—urinary bladder cancer	0.000188	0.000353	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000188	0.00121	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—HRAS—urinary bladder cancer	0.000187	0.00121	CbGpPWpGaD
Imiquimod—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000187	0.000351	CcSEcCtD
Imiquimod—Decreased appetite—Epirubicin—urinary bladder cancer	0.000186	0.000349	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000185	0.000347	CcSEcCtD
Imiquimod—Fatigue—Epirubicin—urinary bladder cancer	0.000185	0.000346	CcSEcCtD
Imiquimod—Pain—Epirubicin—urinary bladder cancer	0.000183	0.000343	CcSEcCtD
Imiquimod—Urticaria—Methotrexate—urinary bladder cancer	0.000182	0.000341	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000182	0.00117	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000181	0.00116	CbGpPWpGaD
Imiquimod—Abdominal pain—Methotrexate—urinary bladder cancer	0.000181	0.000339	CcSEcCtD
Imiquimod—Body temperature increased—Methotrexate—urinary bladder cancer	0.000181	0.000339	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00018	0.000338	CcSEcCtD
Imiquimod—TLR8—Immune System—EGFR—urinary bladder cancer	0.000179	0.00115	CbGpPWpGaD
Imiquimod—Insomnia—Doxorubicin—urinary bladder cancer	0.000179	0.000336	CcSEcCtD
Imiquimod—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000178	0.000334	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000178	0.00114	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000178	0.00114	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL2—urinary bladder cancer	0.000178	0.00114	CbGpPWpGaD
Imiquimod—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000177	0.000331	CcSEcCtD
Imiquimod—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000176	0.000331	CcSEcCtD
Imiquimod—Somnolence—Doxorubicin—urinary bladder cancer	0.000176	0.00033	CcSEcCtD
Imiquimod—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000175	0.000328	CcSEcCtD
Imiquimod—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000174	0.000327	CcSEcCtD
Imiquimod—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000172	0.000323	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000171	0.000321	CcSEcCtD
Imiquimod—Fatigue—Doxorubicin—urinary bladder cancer	0.000171	0.00032	CcSEcCtD
Imiquimod—Urticaria—Epirubicin—urinary bladder cancer	0.00017	0.000319	CcSEcCtD
Imiquimod—Pain—Doxorubicin—urinary bladder cancer	0.000169	0.000318	CcSEcCtD
Imiquimod—TLR8—Immune System—KRAS—urinary bladder cancer	0.000169	0.00109	CbGpPWpGaD
Imiquimod—Body temperature increased—Epirubicin—urinary bladder cancer	0.000169	0.000317	CcSEcCtD
Imiquimod—Abdominal pain—Epirubicin—urinary bladder cancer	0.000169	0.000317	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000169	0.00109	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000169	0.00109	CbGpPWpGaD
Imiquimod—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000169	0.000316	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000168	0.00108	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000168	0.00108	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1A—urinary bladder cancer	0.000168	0.00108	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PTEN—urinary bladder cancer	0.000167	0.00108	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000166	0.00107	CbGpPWpGaD
Imiquimod—Asthenia—Methotrexate—urinary bladder cancer	0.000164	0.000308	CcSEcCtD
Imiquimod—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000163	0.000306	CcSEcCtD
Imiquimod—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000162	0.000304	CcSEcCtD
Imiquimod—Pruritus—Methotrexate—urinary bladder cancer	0.000162	0.000303	CcSEcCtD
Imiquimod—TLR7—Immune System—EP300—urinary bladder cancer	0.000159	0.00103	CbGpPWpGaD
Imiquimod—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000158	0.000296	CcSEcCtD
Imiquimod—Urticaria—Doxorubicin—urinary bladder cancer	0.000157	0.000295	CcSEcCtD
Imiquimod—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000157	0.000294	CcSEcCtD
Imiquimod—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000157	0.000294	CcSEcCtD
Imiquimod—Diarrhoea—Methotrexate—urinary bladder cancer	0.000157	0.000294	CcSEcCtD
Imiquimod—TLR7—Immune System—SRC—urinary bladder cancer	0.000155	0.000998	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000155	0.000997	CbGpPWpGaD
Imiquimod—Asthenia—Epirubicin—urinary bladder cancer	0.000154	0.000288	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000153	0.000983	CbGpPWpGaD
Imiquimod—Pruritus—Epirubicin—urinary bladder cancer	0.000151	0.000284	CcSEcCtD
Imiquimod—Dizziness—Methotrexate—urinary bladder cancer	0.000151	0.000284	CcSEcCtD
Imiquimod—Diarrhoea—Epirubicin—urinary bladder cancer	0.000146	0.000275	CcSEcCtD
Imiquimod—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000146	0.000274	CcSEcCtD
Imiquimod—Vomiting—Methotrexate—urinary bladder cancer	0.000145	0.000273	CcSEcCtD
Imiquimod—Rash—Methotrexate—urinary bladder cancer	0.000144	0.00027	CcSEcCtD
Imiquimod—Dermatitis—Methotrexate—urinary bladder cancer	0.000144	0.00027	CcSEcCtD
Imiquimod—TLR8—Immune System—HRAS—urinary bladder cancer	0.000144	0.000927	CbGpPWpGaD
Imiquimod—Headache—Methotrexate—urinary bladder cancer	0.000143	0.000269	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000143	0.000919	CbGpPWpGaD
Imiquimod—Asthenia—Doxorubicin—urinary bladder cancer	0.000142	0.000267	CcSEcCtD
Imiquimod—Dizziness—Epirubicin—urinary bladder cancer	0.000142	0.000265	CcSEcCtD
Imiquimod—Pruritus—Doxorubicin—urinary bladder cancer	0.00014	0.000263	CcSEcCtD
Imiquimod—Vomiting—Epirubicin—urinary bladder cancer	0.000136	0.000255	CcSEcCtD
Imiquimod—Nausea—Methotrexate—urinary bladder cancer	0.000136	0.000255	CcSEcCtD
Imiquimod—TLR7—Immune System—EGFR—urinary bladder cancer	0.000136	0.000875	CbGpPWpGaD
Imiquimod—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000136	0.000254	CcSEcCtD
Imiquimod—Rash—Epirubicin—urinary bladder cancer	0.000135	0.000253	CcSEcCtD
Imiquimod—Dermatitis—Epirubicin—urinary bladder cancer	0.000135	0.000253	CcSEcCtD
Imiquimod—Headache—Epirubicin—urinary bladder cancer	0.000134	0.000251	CcSEcCtD
Imiquimod—Dizziness—Doxorubicin—urinary bladder cancer	0.000131	0.000246	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.00013	0.000837	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KRAS—urinary bladder cancer	0.000128	0.000826	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000128	0.000826	CbGpPWpGaD
Imiquimod—Nausea—Epirubicin—urinary bladder cancer	0.000127	0.000238	CcSEcCtD
Imiquimod—Vomiting—Doxorubicin—urinary bladder cancer	0.000126	0.000236	CcSEcCtD
Imiquimod—Rash—Doxorubicin—urinary bladder cancer	0.000125	0.000234	CcSEcCtD
Imiquimod—Dermatitis—Doxorubicin—urinary bladder cancer	0.000125	0.000234	CcSEcCtD
Imiquimod—Headache—Doxorubicin—urinary bladder cancer	0.000124	0.000233	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000119	0.000769	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000118	0.000759	CbGpPWpGaD
Imiquimod—Nausea—Doxorubicin—urinary bladder cancer	0.000118	0.000221	CcSEcCtD
Imiquimod—TLR7—Immune System—HRAS—urinary bladder cancer	0.000109	0.000702	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000103	0.000665	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	9.78e-05	0.00063	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NAT1—urinary bladder cancer	9.78e-05	0.00063	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.62e-05	0.00062	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	8.95e-05	0.000576	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	8.06e-05	0.000519	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.96e-05	0.000513	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	7.61e-05	0.00049	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.55e-05	0.000486	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.55e-05	0.000486	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	7.41e-05	0.000477	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.91e-05	0.000445	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.22e-05	0.0004	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.94e-05	0.000383	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—TYMP—urinary bladder cancer	5.93e-05	0.000382	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.87e-05	0.000378	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.72e-05	0.000368	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.69e-05	0.000367	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.36e-05	0.000345	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.63e-05	0.000298	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.57e-05	0.000295	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.29e-05	0.000276	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.29e-05	0.000276	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.26e-05	0.000274	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.16e-05	0.000268	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.14e-05	0.000266	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.09e-05	0.000264	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.57e-05	0.00023	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.45e-05	0.000222	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.35e-05	0.000216	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.31e-05	0.000213	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.31e-05	0.000213	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.21e-05	0.000207	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.92e-05	0.000188	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.88e-05	0.000186	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.79e-05	0.000179	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.68e-05	0.000172	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.67e-05	0.000172	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.65e-05	0.00017	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.65e-05	0.00017	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.54e-05	0.000163	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.49e-05	0.00016	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.34e-05	0.000151	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.22e-05	0.000143	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.07e-05	0.000133	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.04e-05	0.000132	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.04e-05	0.000132	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.96e-05	0.000126	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.92e-05	0.000124	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.9e-05	0.000122	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.82e-05	0.000117	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.81e-05	0.000116	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.49e-05	9.61e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.46e-05	9.43e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.41e-05	9.06e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.3e-05	8.38e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.24e-05	7.99e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.15e-05	7.42e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1e-05	6.47e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.58e-06	6.17e-05	CbGpPWpGaD
